Fifty-two week treatment with secukinumab (Cosentyx) demonstrated clinically significant and sustained superior efficacy compared to ustekinumab (Stelara) in clearing the skin of subjects with moderate to severe psoriasis, with a comparable safety profile, reported Diamant Thaçi, MD, at the Late-breaking Research: Clinical Trials session at the 2016 American Academy of Dermatology meeting on March 5, 2016, in Washington, DC.
The multicenter, double-blind, parallel-group study CLEAR study compares the efficacy and safety of secukinumab with ustekinumab in moderate to severe plaque psoriasis. Subjects were randomized 1:1 to receive secukinumab (300 mg) at Baseline, Weeks 1, 2 and 3, then every 4 weeks from Week 4 to 48, or ustekinumab (dosing per label). The primary objective of superior Psoriasis Area and Severity Index (PASI) 90 response at Week 16 was achieved. The 52-week PASI90 (secondary objective), PASI100, and Dermatology Life Quality Index 0/1 responses (DLQI 0/1; max range 0-30) were presented. At Week 52, secukinumab (N=334) was superior to ustekinumab (N=335), in achieving PASI90 (76.2% vs. 60.6%; P<0.0001) and PASI100 (clear skin) (45.9% vs. 35.8%; P=0.0103) [Multiple Imputation]. Significantly greater DLQI 0/1 responses were also achieved at Week 52 for secukinumab vs ustekinumab (71.6% vs. 59.2%; P=0.0008). Secukinumab had a safety profile similar to that of ustekinumab and consistent with that reported in secukinumab pivotal phase 3 studies.
Fifty-two week treatment with secukinumab (Cosentyx) demonstrated clinically significant and sustained superior efficacy compared to ustekinumab (Stelara) in clearing the skin of subjects with moderate to severe psoriasis, with a comparable safety profile, reported Diamant Thaçi, MD, at the Late-breaking Research: Clinical Trials session at the 2016 American Academy of Dermatology meeting on March 5, 2016, in Washington, DC.
The multicenter, double-blind, parallel-group study CLEAR study compares the efficacy and safety of secukinumab with ustekinumab in moderate to severe plaque psoriasis. Subjects were randomized 1:1 to receive secukinumab (300 mg) at Baseline, Weeks 1, 2 and 3, then every 4 weeks from Week 4 to 48, or ustekinumab (dosing per label). The primary objective of superior Psoriasis Area and Severity Index (PASI) 90 response at Week 16 was achieved. The 52-week PASI90 (secondary objective), PASI100, and Dermatology Life Quality Index 0/1 responses (DLQI 0/1; max range 0-30) were presented. At Week 52, secukinumab (N=334) was superior to ustekinumab (N=335), in achieving PASI90 (76.2% vs. 60.6%; P<0.0001) and PASI100 (clear skin) (45.9% vs. 35.8%; P=0.0103) [Multiple Imputation]. Significantly greater DLQI 0/1 responses were also achieved at Week 52 for secukinumab vs ustekinumab (71.6% vs. 59.2%; P=0.0008). Secukinumab had a safety profile similar to that of ustekinumab and consistent with that reported in secukinumab pivotal phase 3 studies.
Fifty-two week treatment with secukinumab (Cosentyx) demonstrated clinically significant and sustained superior efficacy compared to ustekinumab (Stelara) in clearing the skin of subjects with moderate to severe psoriasis, with a comparable safety profile, reported Diamant Thaçi, MD, at the Late-breaking Research: Clinical Trials session at the 2016 American Academy of Dermatology meeting on March 5, 2016, in Washington, DC.
The multicenter, double-blind, parallel-group study CLEAR study compares the efficacy and safety of secukinumab with ustekinumab in moderate to severe plaque psoriasis. Subjects were randomized 1:1 to receive secukinumab (300 mg) at Baseline, Weeks 1, 2 and 3, then every 4 weeks from Week 4 to 48, or ustekinumab (dosing per label). The primary objective of superior Psoriasis Area and Severity Index (PASI) 90 response at Week 16 was achieved. The 52-week PASI90 (secondary objective), PASI100, and Dermatology Life Quality Index 0/1 responses (DLQI 0/1; max range 0-30) were presented. At Week 52, secukinumab (N=334) was superior to ustekinumab (N=335), in achieving PASI90 (76.2% vs. 60.6%; P<0.0001) and PASI100 (clear skin) (45.9% vs. 35.8%; P=0.0103) [Multiple Imputation]. Significantly greater DLQI 0/1 responses were also achieved at Week 52 for secukinumab vs ustekinumab (71.6% vs. 59.2%; P=0.0008). Secukinumab had a safety profile similar to that of ustekinumab and consistent with that reported in secukinumab pivotal phase 3 studies.
